Host Immune Signatures as Predictors for Immunotherapy Regimens in Patients with Metastatic Renal Cell Carcinoma
In his study presented at the ONCLIVE National Fellows Forum for genitourinary cancers, Marc Machaalani examined how host immune signatures can be used as predictors for immunotherapy regimens in metastatic renal cell carcinoma (RCC) patients, which he elaborates on in this MEDtalk.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
